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What’s new? 
 In Barbados, diabetes-related foot problems account for 89% of hospital admissions,
but in primary care only 41% had a foot examination over a 2-year period. Peripheral 
neuropathy prevalence in a predominantly African descent Caribbean population with 
diabetes is unknown. 
 In people with known and newly diagnosed diabetes, the prevalence of peripheral
neuropathy with a loss of protective sensation was 28.5% (95% CI 22.7 to 34.4) as 
indicated by monofilament testing with ≥ 1 insensate site and/or vibration perception 
threshold > 25 V. Monofilament testing alone identified 98% of such cases in people 
with previously diagnosed diabetes. 
 Monofilament testing alone may be adequate for screening for peripheral neuropathy
with a loss of protective sensation. 
Abstract 
Aims To determine the prevalence and potential risk factors for diabetic peripheral neuropathy 
with a loss of protective sensation in Barbados. 
Methods A representative population sample aged > 25 years with previously diagnosed 
diabetes or a fasting blood glucose ≥ 7 mmol/l or HbA1c ≥ 48 mmol/mol (6.5%) was tested by 
10 g monofilament at four plantar sites per foot and a 28 Hz tuning fork and neurothesiometer 
at the hallux. Data were adjusted to the age structure of people with diabetes in Barbados. 
Multivariable logistic regression assessed associations with peripheral neuropathy with a loss 
of protective sensation. 
Results Of 236 participants [74% response rate, 33% men, 91% black, median age 58.6 years, 
mean BMI 30.1 kg/m
2
, mean HbA1c 54 mmol/mol (7.1%)], 51% had previously diagnosed
diabetes. Foot examination demonstrated that 25.8% (95% CI 20.2 to 31.5) had at least one 
insensate site with monofilament testing, 14.8% (95% CI 10.2 to 19.4) had an abnormal 
tuning fork test and 10.9% (95% CI 6.9 to 14.9) had a vibration perception threshold > 25 V. 
Peripheral neuropathy with a loss of protective sensation prevalence was 28.5% (95% CI 22.7 
to 34.4) as indicated by monofilament with ≥ 1 insensate site and/or vibration perception 
threshold > 25 V. With previously diagnosed diabetes the prevalence was 36.4% (95% CI 
27.7 to 45.2) with 98.4% of cases identified by monofilament testing. Increasing age, 
previously diagnosed diabetes, male sex and abdominal obesity were independently 
associated with peripheral neuropathy with a loss of protective sensation. 
Conclusions Over a third of people with previously diagnosed diabetes had evidence of 
peripheral neuropathy with a loss of protective sensation. Monofilament testing alone may be 
adequate to rule out peripheral neuropathy with a loss of protective sensation. Monofilament 
and neurothesiometer stimuli are reproducible but dependent on participant response. 
Introduction 
Diabetes has an estimated prevalence of 18.7% in people aged ≥ 25 years in Barbados (1). 
Foot problems related to diabetes place a significant burden on the island’s healthcare system. 
For example, the diabetes-related lower extremity amputation rate has been estimated at 936 
per 100 000 people (2) and in 2014 foot disease related to diabetes accounted for 89% of 
diabetes-related admissions to the island’s main hospital (3). 
Diabetes-related peripheral neuropathy, deformity and trauma are the most common factors 
that interact to cause ulceration in people with diabetes (4). Severe peripheral neuropathy 
with a loss of protective sensation (PNLOPS) makes the foot vulnerable to physical and 
thermal trauma and predisposes the foot to deformity. Neuropathy increases the risk of foot 
ulceration and diabetic foot infection 7-fold, and these in turn have a causative role in 61% of 
lower limb amputations (5, 6). Poor footwear choice including the wearing of slippers, a 
common practice in tropical countries, increases the risk to a neuropathic foot (2, 7). 
Risk factors for diabetes-related PNLOPS include increased duration of diabetes, poor 
glycaemic control, dyslipidaemia, hypertension and smoking (8, 9). Frequently, neuropathy 
develops unnoticed and its severity does not correspond to symptoms (5). Screening for foot 
problems along with appropriate interventions may be associated with reduced ulceration and 
amputation rates (8, 10-13), and clinical practice guidelines recommend screening (4, 14-17). 
However, an audit of diabetes primary care in Barbados estimated that over a 2-year period 
only 41% of people with diabetes had evidence of at least one foot examination recorded in 
their charts (18). 
Studies to determine the prevalence of peripheral neuropathy in people with diabetes have 
used different inclusion and diagnostic criteria. In general practice the prevalence in people 
with a new diagnosis of diabetes ranges from 11.5% [mean vibration perception threshold 
(VPT) for both big toes > 25 V] in the UK (19) to 48% (10 g monofilament testing at any of 
the nine sites of each foot) in The Netherlands (20). In Sweden, the prevalence in a 
pulation survey of people with previously diagnosed diabetes was 15% by monofilament 
testing, 24% by tuning fork testing and 29%  by VPT  25 V (21). There have been few 
studies on the prevalence of peripheral neuropathy in people detected by population screening 
for diabetes (previously diagnosed cases plus those newly detected by screening). In 
Mauritius, using a VPT threshold of the population mean + 2 SD, a prevalence of 8.3% was 
estimated (22). In Egypt, the prevalence was 19.9% with neuropathy being identified by the 
Michigan Neuropathy Screening Instrument or nerve conduction tests (23), and in Australia it 
was 10% when two of the four scales used gave abnormal results (24). 
Barbados has a population of approximately 280 000 people, of which 92% is of African 
origin (25). Previous published work on diabetes-related peripheral neuropathy prevalence in 
a similar population is lacking. The objectives of this study were 2-fold: first, to determine 
the prevalence of PNLOPS and, second, to identify potential risk factors for developing 
PNLOPS in a representative sample of the Barbadian population aged ≥ 25 years and 
identified by population screening as having diabetes. 
Methods 
Setting 
This study was nested within the Barbados Health of the Nation (HotN) study, which was 
designed to obtain a representative sample of the adult population aged ≥ 25 years. In total, 
1234 individuals participated in the HotN study between September 2011 and May 2013 (1). 
Study size 
The sample size of this study was contingent on the prevalence of diabetes in the underlying 
HotN study (1). However, it was estimated that the HoTN study would identify at least 270 
people with diabetes, at least 210 of whom would participate. With a sample size of 210 the 
precision (95% confidence intervals) for a prevalence of neuropathy of 25% would be +/- 
6%. 
Inclusion criteria 
People reporting a physician’s diagnosis of diabetes, or who had fasting plasma glucose > 7 
ol l
-1
 or HbA1c > 48 mmol/mol (6.5%) were eligible to take part in the foot study.
Individuals who were unable to comply with the physical examination, such as those with a 
severe mental health disability, were excluded. 
Recruitment 
Ethical approval was obtained from the Institutional Review Board of the University of the 
West Indies. Eligible individuals were invited via telephone to attend the assessment centre. 
A total of up to three missed appointments was permitted. Reimbursement for travel expenses 
was offered. 
Study procedure 
A manual of procedures was developed. Physicians trained in the study procedure conducted 
the foot examination. Data were collected between October 2012 and March 2014. 
Examination and definition of PNLOPS 
The examination was designed to detect PNLOPS rather than to detect early neuropathy (4), 
and utilized methods recommended by the American Diabetes Association (4, 17) and the 
International Working Group on the Diabetic Foot (14). The American Diabetes Association 
recommends that two methods be used. Following the American Diabetes Association 
guidance, PNLOPS was defined as being insensate in at least one examination site and/or a 
VPT > 25 V (4). 
The presence of ulceration and amputation were documented. Neuropathy testing was 
performed in a quiet room with the participant supine. Instructions were first given with the 
sensation demonstrated on the hand or sternum, and then testing was performed with the 
participant’s eyes closed. 
Monofilament testing 
We used 10 g Bailey monofilaments, with no more than 100 applications of any 
monofilament without at least a 24-hour rest period to prevent any fall in monofilament 
accuracy (26). Three applications of the monofilament plus at least one sham application 
were performed at each of four plantar sites (great toe and first, third and fifth metatarsal 
heads), as recommended for testing by the American Diabetes Association (4). Force was 
applied to make the monofilament buckle on skin contact and was maintained for 
approximately 2 seconds. Participants were asked if they felt the pressure (yes/no) and where 
they felt it (right/left foot). Not detecting two out of three applications correctly at any one 
site was considered indicative of PNLOPS (14). 
Vibration sense testing by a 128 Hz tuning fork 
A tuning fork was activated by drawing the prongs together or hitting it against the palm and 
ensuring that the vibration was not audible. It was applied perpendicular to the dorsal aspect 
of the interphalangeal joint of each hallux using the method outlined by the International 
Working Group on the Diabetic Foot (14). Application of the vibrating tuning fork was 
repeated a further two times but was alternated with at least one mock application when it 
was not vibrating. Participants who were unable to detect the vibration two out of three times 
were classified as having PNLOPS (14). 
VPT testing with a neurothesiometer 
A Horwell neurothesiometer was applied to the tip of each hallux with the vibrator head 
making contact under its own weight. The amplitude was slowly increased until the vibration 
was detected, and this reading was recorded. The procedure was repeated twice at each hallux 
and the VPT was the average of the three readings. VPT > 25 V was assessed as indicative of 
PNLOPS and being predictive of ulceration (4). 
Anthropometric and biological measurements 
Anthropometric and biological measurements were made as part of the Barbados HoTN 
study, and the methods used have been described in detail elsewhere (1, 27). Height, weight, 
waist and hip circumference, and blood pressure (using an Omron HEM-705CP digital 
machine) were measured by trained and accredited data collection staff. A venous blood 
sample, taken after an overnight fast of at least 9 hours, was collected in a sodium fluoride 
EDTA tube. Plasma glucose was measured at the Barbados Reference Laboratory using the 
glucose hexokinase method on a Roche Cobas 6000 analyser. The Barbados Reference 
Laboratory is internationally accredited with the American College of Pathologists. 
Lipids and HbA1c were analysed at the George Alleyne Chronic Disease Research Centre 
(total cholesterol, HDL and triglycerides) using a Reflotron biochemical analyser and a DCA 
2000 analyser, respectively, following the manufacturers’ quality control procedures 
throughout. In addition, 56 duplicate samples were analysed in the Barbados Reference 
Laboratory to align all lipid and HbA1c results with the methods used in the reference 
laboratory. The method used by the DCA 2000 analyser is certified by the National 
Glycohemoglobin Standardisation Program; samples are directly traceable to the Diabetes 
Control and Complications Trial reference and are not affected by common haemoglobin 
variants such as HbC and HbS (27-29). Glucose-6-phosphate dehydrogenase variants that 
could decrease HbA1c values (30) were not excluded. 
Statistical analyses 
Data were analysed using Stata statistical software (version 13, StataCorp, College Station, 
TX, USA). Categories of previously and newly diagnosed diabetes were created following 
the criteria described under ‘inclusion criteria’. Categories of PNLOPS were created based on 
the findings from monofilament, tuning fork and neurothesiometer testing following the 
criteria described in Methods. The prevalence of PNLOPS is reported with the study 
population weighted to the age and sex structure of the adult population with diabetes in 
Barbados, as recorded in the HotN study (1, 27). 
Comparisons were made between two types of subgrouping. First, the prevalence of PNLOPS 
was compared between those with previously diagnosed diabetes and those with newly 
detected diabetes. Second, the age, sex, diabetes, anthropometric and biological 
characteristics were compared between those with and without PNLOPS. Differences 
between both groups are presented with 95% confidence intervals and P-values. The Stata 
module ‘cendif’ was used to calculate 95% confidence intervals on the difference between 
two medians. 
Finally, logistic regression was used to identify independent potential risk factors for 
PNLOPS. A backward step selection process was used, starting with all variables in the 
model that were associated with PNLOPS with P < 0.10. Gender, given its potential 
importance as a determinant, was also entered into the initial logistic model, although it 
marginally failed to meet the P < 0.10 criterion. The least significant variable was removed at 
each step until all variables in the final model were associated with PNLOPS with P < 0.10. 
Two logistic regression models were run, one in which waist circumference was entered as a 
continuous variable, and the other in which abdominal obesity was defined using gender-
specific cut-off points (> 94 cm in women, > 102 cm in men).  
Results 
Of 320 eligible persons, 236 participated in this study giving a 73.8% response rate. Figure 1 
shows the number of eligible participants and the reasons for non-participation. Of the 
responders, 50.8% had a physician’s prior diagnosis of diabetes while the rest were identified 
by screening for diabetes during the HotN study. A greater proportion of the non-responders 
compared with responders (66.7% vs. 50.8%, P = 0.012) had a physician’s prior diagnosis of 
diabetes. Non-responders were people who were eligible to take part in this study but chose 
not to. The characteristics of responders (Table 1) were as follows: 33.1% men, median age 
58.6 years (IQR 50.6 to 69.4, range 29.6–95.7), 90.7% of African descent, mean BMI 30.1 
m
2
, mean waist circumference 97.7 cm, 52.1% on medication for hypertension, mean total
olesterol 4.9 mmol l
-1
, mean HDL 1.3 mmol l
-1
, mean fasting blood glucose 7.2 mmol l
-1
and mean HbA1c 54 mmol/mol (7.1%). 
The data were adjusted to reflect the age structure of people with diabetes in Barbados. The 
prevalence of PNLOPS, as determined by at least one insensate site on monofilament, tuning 
fork and neurothesiometer testing separately, was 25.8, 14.8 and 10.9%, respectively. The 
prevalence of PNLOPS as detected by monofilament and/or neurothesiometer testing was 
28.5% (Table 2); monofilament testing identified 90.5% of these cases. For those with 
previously diagnosed diabetes only, the prevalence of PNLOPS as detected by monofilament 
and/or neurothesiometer testing was 36.4%, with 98.4% of these cases identified by 
monofilament testing. For the overall sample, the prevalence of PNLOPS as identified by 
both a VPT > 25 V and one, two, three or four total insensate sites for both feet combined, 
was 7.3, 7.3, 6 and 6%, respectively. 
Bivariate analysis factors associated with PNLOPS, as detected by monofilament and/or 
neurothesiometer testing, included previously diagnosed diabetes, increasing age, waist 
circumference, systolic blood pressure and triglyceride levels (P < 0.05) (Table 3). 
Multivariable logistic regression identified increasing age in 10-year bands (OR 1.92, 95% CI 
1.46 to 2.53), male sex (OR 2.27, 95% CI 1.13 to 4.53), previously diagnosed diabetes (OR 
2.13, 95% CI 1.09 to 4.16) and abdominal obesity (OR 2.31, 95% CI 1.17 to 4.55) as being 
independently associated with PNLOPS (Table 4, model 2). 
Discussion 
This is the first population-based study of PNLOPS in people with diabetes for a population 
of predominantly African descent. In our study, the prevalence of PNLOPS ranged from 10.9 
to 25.8% depending on the test used. Clinical guidelines (4, 17) recommend using two 
methods to diagnose PNLOPS. Using a VPT > 25 V and/or at least one insensate site by 
monofilament testing as the definition, the prevalence was 28.5% for all people with diabetes, 
and increased to 35.8% for people with previously diagnosed diabetes. With this combination 
of tests, 90.5% of all cases of PNLOPS were detected by monofilament testing, and this 
increased to 98.4% when only people previously diagnosed with diabetes were tested. 
Clinical practice guidelines place these individuals in an increased risk category warranting 
more frequent follow-up with attention to footwear and education on foot care (4, 14).  
Increasing age and male gender, previously diagnosed diabetes and increasing waist 
circumference, were independently associated with PNLOPS. Using any of the recommended 
thods (monofilament, tuning fork or neurothesiometer testing), people with previously 
diagnosed diabetes had a significantly higher prevalence of PNLOPS than those newly 
detected by screening. Poor glycaemic control and older age are recognized risk factors for 
neuropathy (31). 
Variations in diagnostic protocols and study populations hamper comparison with other 
studies. Clinical guidelines also vary in their recommendations regarding test methods and 
sites to be tested. In Sweden, the prevalence in a population survey of people with previously 
diagnosed diabetes was 15% by monofilament testing, 24% by tuning fork testing and 29% 
by VPT  25 V (21) compared with 35.8, 23.8 and 14.6%, respectively, in this study. In the 
USA, using data from the National Health and Nutrition Examination Survey (NHANES) for 
1999–2004 (32), in which peripheral neuropathy was defined as at least one insensate site 
detected by monofilament testing (three sites tested per foot), the prevalence was 18% for 
newly diagnosed diabetes and 27% for previously diagnosed diabetes. This was more in line 
with the monofilament test results from our study. However, unlike our study, where 49.2% 
were newly diagnosed, only 15% were newly diagnosed in the NHANES. In a Dutch 
population-screening study (20), neuropathy prevalence by single insensate monofilament 
site was 48% in either previously diagnosed or newly diagnosed compared with 35.8 and 
15.0%, respectively, in this study. In the Dutch study, however, nine sites were tested in each 
foot compared with four in this study. Testing nine sites may decrease the specificity of the 
test that is dependent on the response of the test subject. In China, the prevalence was 8.6% 
by monofilament and 14% by tuning fork testing, but the exact testing and diagnostic criteria 
were not described (33). 
Strengths and limitations 
This study’s strengths are that a representative population-based sample of people with 
previously diagnosed and newly identified diabetes was tested for neuropathy by clearly 
described methods and protocols recommended for routine clinical use (4, 14). Both 
monofilament and tuning fork testing should be readily available in primary care clinics in 
Barbados. Several limitations also need to be taken into consideration. This study examined a 
small sample of people from largely the same ethnic group and thus results may not be 
generalizable to other countries or ethnic groups. Although the response rate was 74% for this 
study, there was only a 55% response rate for the HotN study (1) that identified the 
population with diabetes. This could affect the representativeness of the sample. New cases 
of diabetes were diagnosed by a single fasting blood glucose or HbA1c test, which would 
result in overdiagnosis of diabetes. The tuning fork test protocol (14) could lead to variations 
in intensity of the vibration used to judge whether neuropathy is present. The method 
advocated by the Michigan Neuropathy Screening Instrument, where vibration is scored as 
present if the examiner senses the vibration on their finger for < 10 seconds longer than the 
patient, may be more reproducible (34). However, the vibration of the neurothesiometer 
would be reliable and reproducible, even if the cut-off of 25 V might not be fully validated. 
All tests used depended on participant response to the stimulus. 
Implications for research and/or practice 
Over a third of people with diabetes attending clinic for diabetes follow-up in a population of 
predominantly African descent, with a high prevalence of diabetes and diabetes-related foot 
problems, will have PNLOPS identified by monofilament testing. A chart audit (18) indicated 
that only 41% of people with diabetes attending primary care in this setting had a foot 
examination in the previous 2 years, and the quality of that examination was undetermined. 
Based on our study outcomes, we postulate that in contrast to existing guidelines, people with 
diabetes attending for follow-up need only be tested by monofilament to rule out PNLOPS, as 
98.4% of cases were identified by monofilament testing alone. This may result in a more 
efficient use of clinical resources and in a higher proportion of people with diabetes having a 
foot examination in a busy clinic setting. This study also supports the need for a foot 
examination for neuropathy in newly diagnosed diabetes, as 20% were found to have 
PNLOPS. 
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(N = 120) 
Newly detected 
diabetes 
(N = 116) 
All diabetes Total 
(N)
Gender [N (%)] 
Male 41 (34.2) 37 (31.9) 78 (33.1) 78 
Female 79 (65.8) 79 (68.1) 158 (66.9) 158 
Age 
Median (IQR) 61.6 (52.2 to 72.6) 56.7 (48.6 to 66.3) 58.6 (50.6 to 69.4) 236 
Range (years) 33 - 89 30 - 96 30-96 
Ethnicity (%) 
Black 90.8 90.5 90.7 214 
White 3.3 0 1.7 4 
East Indian 2.5 0.9 1.7 4 
Other 3.3 8.6 5.9 14 
Diabetes duration (years) 
Median (IQR) 5.6 (2.9 to 15.4) 0 0 (0 to 5.6) 236 
Ulceration/amputation (%) 8.3 0 4.2 236 
Current smoker (%) 1.7 4.3 3 236 
Systolic blood pressure 
(mmHg) 
137.7 (18.1) 136.2 (20.8) 136.8 (19.5) 236 
Diastolic blood pressure 
(mmHg) 






Total cholesterol 4.8 (1.1) 4.9 (0.9) 4.9 (1.0) 226 
HDL cholesterol 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 226 
Triglycerides 1.1 (0.5) 1.1 (0.6) 1.1 (0.5) 226 
Fasting glucose
a,b
 (mmol l-1) 8.1 (3.9)
a
 6.4 (1.7) 7.2 (3.1) 226 
HbA1c
a
 (mmol/mol [%]) 60 (20), [7.6 (1.8)]  49 (11), [6.6 (1.0)]  54 (16), [7.1 (1.5)] 226 
a
N for people with previously diagnosed diabetes (110). 
b
Fasting venous plasma sample. 
TABLE 2 Prevalencea of peripheral neuropathy with a loss of protective sensation by method of 
detection in those with previously diagnosed and newly detected diabetes  
Method of diagnosis 
Previously diagnosed 
diabetes 
[% (95% CIb)] 
Newly detected 
diabetes 
[% (95% CI)] 
Total 
[% (95% CI)] 
Monofilamentc ≥ 1 site 35.8 (27.0 to 44.7) 15.0 (8.4 to 20.6) 25.8 (20.2 to 31.5) 
Difference (95% CI) 20.8 (10.0 to 31.6) 
Monofilament ≥ 2 sites 29.9 (21.5 to 38.4) 6.8 (2.1 to 11.4) 18.8 (13.7 to 23.9) 
Difference (95% CI)  22.6 (13.2 to 32.0) 
Monofilament ≥ 3 sites 19.9 (12.6 to 27.3) 5.8 (1.5 to 10.1) 13.1 (8.8 to 17.5) 
Difference (95% CI) 14.1 (5.7 to 22.5) 
Monofilament ≥ 4 sites 17.3 (10.4 to 24.3) 4.1 (0.4 to 7.7) 10.9 (6.9 to 15.0) 
Difference (95% CI) 13.3 (5.5 to 21.0) 
Tuning fork 23.8 (16.1 to 31.5) 4.8 (8.6 to 8.8) 14.8 (10.2 to19.4) 
Difference (95% CI) 19.0 (10.5 to 27.5) 
Neurothesiometer > 25V 14.6 (8.2 to 21.0) 6.9 (2.2 to 11.5) 10.9 (6.9 to 14.9) 
Difference (95% CI) 7.8 (-0.01 to 15.6) 
Monofilament and/or 
neurothesiometer 
36.4 (27.7 to 45.2) 19.8 (12.4 to 27.1) 28.5 (22.7 to 34.4) 
Difference (95% CI) 16.6 (5.3 to 27.9) 
aFigures weighted to the age and sex structure of people with diabetes in Barbados. 
bConfidence interval. 
cMonofilament testing performed at 8 sites (4 per foot). 
TABLE 3 Comparison of characteristics of those with and without peripheral neuropathy with a loss 
of protective sensationa. Figures are means (SD) unless otherwise stated.   
Peripheral neuropathy Difference P-value N 
Risk factor Absent Present (95% CI) 




Male (%) 30.3 41.0 -10.7 (-24.8 to 3.4) 0.1261 236 
Known diabetesb 
(%) 
45.1 67.2 -22.1 (-36.0 to -8.2) 0.0030 236 




96.5 (13.3) 100.9 (13.0) -4.4 (-8.3 to -0.5) 0.0274 231 
Treated blood 
pressure (%) 
48.6 62.3 -13.7 (-28.0 to 0.5) 0.0647 236 
Systolic blood 
pressure (mmHg) 
135.3 (19.0) 141.2 (20.4) -5.9 (-11.6 to -0.3) 0.0407 236 
HDL (mmol l-1) 1.3 (0.3) 1.3 (0.3) 0.0 (-0.1 to 0.1) 0.7467 226 
Triglycerides 
(mmol l-1) 







-2 (-8 to 2),  
[-0.2 (-0.7 to 0.2)] 
0.3392 226 
aPeripheral neuropathy with a loss of protective sensation defined as at least one insensate site by 
monofilament testing and/or vibration perception threshold > 25 V. 
bPreviously diagnosed diabetes. 
TABLE 4 Factors independently associated with peripheral neuropathy with a loss of protective 
sensationa.  
OR (95% CI) P-value 
Model 1b 
Age in 10-year groups 1.95 (1.48 to 2.58) < 0.001 
Previously diagnosed diabetes 2.08 (1.07 to 4.04) 0.031 
Waist circumference (cm) 1.04 (1.01 to 1.06) 0.005 
Model 2c 
Age in 10-year groups 1.92 (1.46 to 2.53) < 0.001 
Male 2.27 (1.13 to 4.53) 0.021 
Previously diagnosed diabetes 2.13 (1.09 to 4.16) 0.026 
Abdominal obesity 2.31 (1.17 to 4.55) 0.015 
aPeripheral neuropathy severe enough to cause a loss of protective sensation, defined as at least one 
insensate site by monofilament testing and/or VPT > 25 V. 
bAll variables with a P-value of < 0.1 from Table 3, plus gender, were entered. Backward step 
regression was performed removing variables sequentially where the P-value was > 0.1, leaving the 
final model as shown. 
cAll variables in model 1 converted to categorical variables. Abdominal obesity is based on a cut 
point of > 94 cm for women, and > 102 for men. 
OR, odds ratios (95% confidence intervals) from logistic regression. 
FIGURE 1 Study recruitment 
